Opus Genetics IRD Effective Income Tax Rate Reconciliation Acquired In Process Research And Development Percent

Effective Income Tax Rate Reconciliation Acquired In Process Research And Development Percent at other companies

eXp World Holdings, Inc. Common StockAGNT

2.1%+1.1pp

Relmada Therapeutics, Inc.RLMD

1.4%-0.7pp

TRV

Trevi Therapeutics, Inc.TRVI

-2.7%+0.6pp

Mativ HoldingsMATV

-0.6%—

Silvaco Group, Inc.SVCO

-3%—

EyePoint, Inc. EYPT

-1.3%+0.1pp

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:EffectiveIncomeTaxRateReconciliationAcquiredInProcessResearchAndDevelopmentPercent.

The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's effective income tax rate reconciliation acquired in process research and development percent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's effective income tax rate reconciliation acquired in process research and development percent?: Opus Genetics (IRD) reported effective income tax rate reconciliation acquired in process research and development percent of -12.6% in Q4 2024.
What does effective income tax rate reconciliation acquired in process research and development percent mean?: Represents the tax rate impact of acquired in-process research and development costs. It is a critical indicator for biopharmaceutical companies assessing the tax treatment of R&D assets obtained through acquisitions.